Experimental cancer drug trial halted early
Disease control
Terminated
This early-stage study tested a new drug called VVD-130850 in 132 people with advanced solid tumors or blood cancers. The goal was to see if it is safe and how the body processes it, both alone and with an immunotherapy. The trial was terminated, so results are limited.
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC